Last year, the company also secured orphan designation for investigational drug candidate to treat glioblastoma. OS2966 selectively blocks CD29 (integrin b1 subunit), a dominant molecule modulating cell interactions
Dexamethasone is being developed for administration as a one-time, bioresorbable intracanalicular plug for drug release to the ocular surface for up 30 days. A total of 40 patients
Nefecon is a new oral modified-release capsule of the corticosteroid, budesonide, being developed to treat patients with IgA nephropathy (IgAN) at risk of developing end-stage renal disease (ESRD),
Currently, the company has completed patient enrollment in a Phase III trial and it expects induction response rate data to be available in the second quarter of 2015.
Recently, Spiriva Respimat was approved by the US Food and Drug Administration (FDA) for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)
Offering a new treatment option for psoriasis patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A and inhibit interaction with the
The Phase II clinical trial is currently underway in nine countries, and will involve around 50 sites. Primary objective of the trial is to determine the most effective
The trial supports the company’s larger clinical program of CVC in non-alcoholic steatohepatitis (NASH), a disease associated with multiple comorbidities, including diabetes. The company said that pioglitazone is
Currently, VS-5584 is being evaluated in a Phase I clinical trial in patients with advanced solid tumors and a Phase I combination trial with VS-6063 (defactinib) in patients
Vayacog is a proprietary prescription medical food that offers phosphatidylserine enriched with DHA, a lipid composition essential to manage key biochemical modifications underlying losses in brain function. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.